A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma

NCT02383368 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

39

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Refractory Solid Tumors
Advanced Cancer

Interventions

DRUG: ASP4132

Sponsor

Astellas Pharma Global Development, Inc.